News from prosonix A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 11, 2014, 04:00 ET

Prosonix Confirms the Potential of its Multi-Component Particle™ Technology for Developing Novel Inhaled Dual and Triple Combination Therapies for Respiratory Diseases

Successful Completion of Biomedical Catalyst Programme  Prosonix, an innovative speciality pharmaceutical company developing a portfolio of...

Sep 02, 2014, 04:00 ET

Prosonix' Marketing Authorisation Application for PSX1001 - a Generic Version of GlaxoSmithKline's Flixotide® Evohaler® - Under Assessment in EU

Triggers milestone payment from Mylan  Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled...

May 15, 2014, 04:00 ET

Prosonix to Present Results of Phase 2 Clinical Study of PSX1002 in Chronic Obstructive Pulmonary Disease (COPD) at the American Thoracic Society Meeting

First full presentation of data from randomised clinical study of glycopyrronium bromide made using Prosonix' novel particle-engineering...

Apr 15, 2014, 08:00 ET

Prosonix and Mylan Enter Into Global Licensing Agreement for Generic Versions of Inhaled Respiratory Products Flixotide® and Flovent®

Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, today announced that...

Jan 23, 2014, 04:00 ET

Prosonix Reports Positive Top-line Results from its Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

First clinical data from PSX1002, a novel, orally inhaled, drug-only, pMDI suspension formulation of glycopyrronium bromide, a long-acting...

Aug 16, 2013, 04:00 ET

Final Patient Completes Prosonix' Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

PSX1002 is a novel, orally inhaled, drug-only, pMDI suspension formulation of glycopyrronium bromide, a long-acting muscarinic antagonist...

Jul 01, 2013, 04:00 ET

Prosonix Appoints Frank Condella as Non-executive Director

Brings further international experience in the development and commercialisation of respiratory medicines Prosonix, an innovative speciality...

May 22, 2013, 02:00 ET

Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix' particle...

Jul 05, 2012, 04:00 ET

Prosonix Enters Collaboration With Imperial College London to Accelerate Development of Engineered Combination Respiratory Medicines (Multi-component Particles™, MCPs™)

Prosonix (Oxford, UK) announced that it has signed a Collaborative Research Agreement with Imperial College London to accelerate the development...